Evidence mapPaperPMID 42246992Full record

ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2026

[Performance-related substance use in everyday life and work].

Sascha Milin, Felix A Ebel, Ingo Schäfer

Abstract readEnglish AbstractReview
In one paragraph

Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sascha MilinKlinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland. s.milin@uke.de.
Felix A EbelKlinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Ingo SchäferKlinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of potential performance-enhancing substances in everyday and working life is often linked to an increased workload, time pressure and limited opportunities for rest. This narrative review summarises recent studies on contexts of use, motives, substance groups, prevalence rates, and benefits and risks.The studies show that the use of performance-enhancing substances is primarily intended to support short-term performance demands. It occurs in particular in cases of fatigue, high cognitive demands, stress, emotional strain and physical complaints at work, including in connection with presenteeism. The substances used include stimulants, mood- or sleep-regulating agents, painkillers and dietary supplements. With the exception of the latter, these substances are often prescription-only; some stimulants are illegal. Prevalence figures vary widely due to differing study methods, settings and definitions of performance-enhancing substances. Generally accepted substances are used more frequently.The benefits of these substances are generally described as limited and context dependent. Key risks include the development of tolerance, dependence, residual effects and impairments affecting safety. Short-term benefits are often offset by long-term health and functional costs. In the context of public health and occupational medicine, performance-related substance use may indicate structural stressors. Prevention, care and work design should aim to ensure long-term functional capacity.

Indexed as

Substance-Related DisordersWorkloadWork PerformanceGermanyHumansRisk FactorsNeuroenhancementPerformance-related substance usePresenteeismPublic healthWork environment

Identifiers

PMID42246992
PMCPMC13323614

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.